Please use this identifier to cite or link to this item: http://repositorio.unicamp.br/jspui/handle/REPOSIP/347840
Type: Artigo
Title: Long‐term treatment of familial male‐limited precocious puberty (testotoxicosis) with cyproterone acetate or ketoconazole
Author: Almeida, Madson Queiroz
Brito, Vinicius Nahime
Lins, Thereza Selma S.
Guerra-Junior, Gil
Castro, Margaret de
Antonini, Sonir Roberto
Arnhold, Ivo Jorge Prado
Mendonca, Berenice Bilharinho
Latronico, Ana Claudia
Abstract: Familial male‐limited precocious puberty (FMPP) or testotoxicosis is a rare gonadotrophin‐independent form of sexual precocity caused by constitutively activating mutations of the LH receptor. Several clinical therapeutic approaches have been reported for this disorder, but with a paucity of long‐term outcome data. Objective To evaluate the long‐term treatment of testotoxicosis with cyproterone acetate or ketoconazole. Design A multicentric retrospective clinical study. Patients Ten boys from eight unrelated Brazilian families who carried known LH‐receptor activating mutations were treated with 70 mg/m2 cyproterone acetate (n = 5) or 10 mg/kg ketoconazole (n = 5) for a mean period of 5 and 8 years, respectively. Measurements Chronological and bone ages, bone age/chronological age ratio, target height (TH) range, adult height, basal and GnRH‐stimulated gonadotrophin levels and basal testosterone levels were assessed. Results Growth velocity decreased significantly during treatment with cyproterone acetate or ketoconazole when compared to pretreatment value in each group (P < 0·05). Bone age/chronological age ratio decreased significantly after cyproterone acetate or ketoconazole therapy. Basal testosterone levels were significantly lower in patients undergoing ketoconazole compared to cyproterone acetate treatment [0·6 ± 0·3 nmol/l (42 ± 21 ng/dl) vs. 5·6 ± 4·0 nmol/l (392 ± 280 ng/dl); P < 0·05], as expected. Secondary gonadotrophin‐dependent precocious puberty occurred at a similar frequency (40%) in both groups. Five patients have attained adult height and two patients have already reached 90% of their adult height. Two of them achieved their TH range and one patient, for whom TH was not available, had an adult height of 0·3 SDS. Four boys (two in each group) did not attain their TH range. Conclusion Long‐term treatment with cyproterone acetate or ketoconazole resulted in similar outcomes without important side‐effects in boys with testotoxicosis. However, both therapies showed limited efficacy in attaining normal adult height
Subject: Puberdade precoce
Country: Reino Unido
Editor: Wiley
Rights: Fechado
Identifier DOI: 10.1111/j.1365-2265.2007.03160.x
Address: https://onlinelibrary.wiley.com/doi/full/10.1111/j.1365-2265.2007.03160.x
Date Issue: 2008
Appears in Collections:FCM - Artigos e Outros Documentos

Files in This Item:
File Description SizeFormat 
000256852400012.pdf204.22 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.